Keros Therapeutics Files 8-K
Ticker: KROS · Form: 8-K · Filed: Dec 3, 2024 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Dec 3, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $200.0 million, $370.0 million, $740.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
Keros Therapeutics signed a material definitive agreement, filing an 8-K on Dec 3, 2024.
AI Summary
On December 3, 2024, Keros Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements/exhibits, but specific details of the agreement, dollar amounts, or other parties involved are not provided in this excerpt.
Why It Matters
This filing indicates a significant new agreement for Keros Therapeutics, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant implications, but the lack of specific details in the provided text makes a precise risk assessment difficult.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- December 3, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement filed by Keros Therapeutics?
The provided excerpt does not specify the details of the material definitive agreement.
Who are the other parties involved in the material definitive agreement?
The excerpt does not mention the other parties to the agreement.
What is the effective date of the material definitive agreement?
The filing date is December 3, 2024, and this is also the date of the earliest event reported, suggesting the agreement is effective around this time.
Are there any financial implications or dollar amounts associated with this agreement mentioned in the filing?
The provided text does not include any specific dollar amounts or financial details related to the agreement.
What other items are included in this 8-K filing besides the material definitive agreement?
The filing also includes information on 'Other Events' and 'Financial Statements and Exhibits'.
Filing Stats: 867 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2024-12-03 07:01:37
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
- $200.0 million — ke an upfront payment to the Company of $200.0 million. In addition to the upfront payment, th
- $370.0 million — ed to receive up to an aggregate of (i) $370.0 million upon the achievement of specified devel
- $740.0 million — ent and commercial milestones; and (ii) $740.0 million upon the achievement of specified sales
Filing Documents
- kros-20241203.htm (8-K) — 40KB
- exhibit99112324pr.htm (EX-99.1) — 13KB
- 0001664710-24-000097.txt ( ) — 182KB
- kros-20241203.xsd (EX-101.SCH) — 2KB
- kros-20241203_lab.xml (EX-101.LAB) — 22KB
- kros-20241203_pre.xml (EX-101.PRE) — 13KB
- kros-20241203_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On December 3, 2024, Keros Therapeutics, Inc. (the "Company") entered into an Exclusive License Agreement (the "Agreement") with Takeda Pharmaceuticals U.S.A., Inc. ("Takeda"). Under the terms of the Agreement, the Company has granted Takeda the exclusive right to develop, manufacture, and commercialize the Company's product candidate, elritercept (KER-050), and certain derivative compounds. This exclusive right applies globally, excluding the territories of mainland China, Hong Kong, and Macau (the "Territory"). Under the Agreement, Takeda will make an upfront payment to the Company of $200.0 million. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of (i) $370.0 million upon the achievement of specified development and commercial milestones; and (ii) $740.0 million upon the achievement of specified sales milestones. If a licensed product is approved for marketing in the Territory, the Company will be entitled to receive royalty payments based on tiered increments of annual net sales in the Territory, with such percentage ranging from the low double-digits to high teens, subject to specified potential royalty reductions. Takeda's obligation to pay royalties for a given licensed product in a given country in the Territory will begin on the date of the first commercial sale for such licensed product in such country and continue until the latest of (i) 10 years from the date of the first commercial sale for such licensed product in such region, (ii) the expiration of the last valid claim of certain licensed patents, and (iii) expiration of regulatory exclusivity in such region. The Agreement will continue in force until the expiration of the royalty term. Takeda may terminate the Agreement (i) in its entirety or on a country-by-country basis for convenience, with notice or (ii) if Takeda reasonably determines that the development, manufacture, and commercialization o
01 Other Events
Item 8.01 Other Events. On December 3, 2024, the Company issued a press release announcing it entered into the Agreement with Takeda. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated December 3 , 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: December 3, 2024